attenuated after adjusting for confounders (REM -1.50, 1.38 and 1.27).
Methods: From 1973 to 2009, 2000+ EPCs were managed in
Nottingham. Oestrogen receptor (ER) was assessed by immunohistochemistry (giving an H-score) on core biopsy for all patients. A total of 831 patients had primary surgery and 575 had good quality tumour samples available for tissue microarray analysis.
Results: Comparing these 831 patients with a younger (<70 years) series (N = 1809), expression of ER (p < 0.001), p53, HER4, CK14, bcl2 (p < 0.000) and CK 17 (p < 0.05) was found to increase with age, while reverse was seen with CK 7/8 (p < 0.002), ki67
and E-Cadherin (p < 0.000). No change was observed in PR, HER2, CK5/6, CK19 and MUC1 expression.
At 66-month median follow-up, for those who did not receive adjuvant systemic therapy (N = 306), tumour size (p < 0.042), grade (p < 0.046), axillary stage (p < 0.000) and PR (p < 0.017) were found to be independent prognostic factors.
At 49-month median follow-up, for patients with ER+ (Hscore P 50) tumours, those with H-score P 250 had equivalent 5-year breast cancer specific survival (BCSS) regardless of primary treatment (surgery vs primary endocrine therapy (PET) 95% versus 93%, p = 0.715). For patients on PET, all those with Hscore P 250 achieved clinical benefit as compared to 11 patients with H-score < 250 who progressed, at 6 months (p < 0.03), the former also had better BCSS (p < 0.01). Dysregulated let-7 expression is associated with many malignancies including breast cancer, and it is hypothesized that defective interaction between let-7 and its target KRAS underpins this association and oncogenesis. We hypothesized that a single nucleotide polymorphism (SNP) in the let-7-binding site in KRAS disrupts let-7 regulation of the oncogene and thus predisposes to breast cancer.
Conclusion
Methods: A population analysis of the association of the KRAS variant and breast cancer was performed on a cohort of 1010 breast cancer patients and 1497 age-matched healthy controls.
Genomic DNA isolated from all participants was amplified using PCR assays designed specifically to identify the T (wild type) or G (variant) allele. Genotyping results were correlated with patients' clinicopathological parameters. In a large, prospective study of postmenopausal middle-aged women, adjusted relative risks (RR), according to BMI in middle age and relative adiposity at age 10, were estimated by Cox regression. (Analyses were confined to non-users of hormone replacement therapy, which can mask the effects of BMI on breast cancer risk.)
Among 397,339 women, there were 6189 incident breast cancers over 5.2 years mean follow-up (average age at diagnosis: 63 years).
As expected, women with a high BMI in middle age had a greater breast cancer risk (P < 0.001). In contrast, women who were plumper than average at age 10 had a lower risk of breast cancer than women who were about average (P < 0.001). A similar apparently protective effect of childhood adiposity was observed at each level of women's BMI in middle age (P = 0.08, NS, for interaction). These relationships were not altered by height (P = 0.9), age at menarche The mean endpoint was Local Recurrence (in breast) (LR).
Entry was to 4-way randomisation: RT only, Tamoxifen (TAM) only, neither, both.
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